GSK (GSK) vs Organon (OGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Organon (OGN) has outperformed GSK (GSK) over the past year, gaining 34.3% versus a gain of 7.4%. Over five years, GSK leads with a +19.3% price change compared with -60.6% for OGN. GSK is the larger company by market cap ($93.24 billion vs $3.61 billion), about 25.8 times the size.
On valuation, Organon trades at a lower forward P/E (3.8x vs 9.4x for GSK). GSK offers the higher dividend yield (1.46% vs 0.58%).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GSK | OGN |
|---|---|---|
| Share price | $46.54 | $13.75 |
| Market cap | $93.24B | $3.61B |
| 1-day change | -1.02% | -0.29% |
| YTD return | -5.10% | +91.77% |
| 1-year return | +7.36% | +34.28% |
| 5-year return | +19.30% | -60.59% |
| P/E ratio (TTM) | 14.68 | 17.63 |
| Forward P/E | 9.42 | 3.80 |
| EPS (TTM) | $3.17 | $0.78 |
| Dividend yield | 1.46% | 0.58% |
| Annual dividend | $0.68 | $0.08 |
| Revenue (latest FY) | — | $6.22B |
| Revenue growth (YoY) | — | -2.92% |
| Net income (latest FY) | — | $187.00M |
| Gross margin | — | 53.30% |
| Net margin | — | 3.01% |
| 52-week high | $61.70 | $13.80 |
| 52-week low | $42.85 | $5.69 |
| Distance from 52-week high | -24.57% | -0.36% |
| Analyst consensus | hold | none |
| Avg. price target upside | +27.48% | -18.18% |
| Average volume | 3.85M | 2.66M |
| Shares outstanding | 2.00B | 262.61M |
| Employees | 66,841 | 10,000 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GSK is about 25.8 times larger than Organon by market value ($93.24B vs $3.61B).
- OGN has outperformed GSK by 26.9 percentage points over the past year.
About GSK
GSK stock →GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments.
Health Care · Biotechnology: Pharmaceutical Preparations · 66,841 employees
About Organon
OGN stock →Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 10,000 employees
GSK vs OGN FAQ
Which is bigger, GSK or Organon?
GSK (GSK) is larger, with a market capitalization of $93.24B compared with $3.61B for Organon (OGN).
Which stock has performed better over the past year, GSK or OGN?
OGN returned +34.28% over the past 12 months, compared with +7.36% for GSK (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, GSK or OGN?
GSK has the lower trailing P/E at 14.7, versus 17.6 for OGN. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, GSK or Organon?
GSK has the higher yield at 1.46%, compared with 0.58% for Organon.
Are GSK and Organon in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.